Caitlin M. Stewart

Caitlin M. Stewart

Auto-generated profile, based on publicly available information

Caitlin M. Stewart

Memorial Sloan Kettering Cancer Center, New York, New York, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Cell
Verified
Journal Article
Open access
EMElizabeth P. Murchison
Elizabeth P. Murchison
OSOle B. Schulz-Trieglaff
Ole B. Schulz-Trieglaff
ZNZemin Ning
Zemin Ning
LALudmil B. Alexandrov
Ludmil B. Alexandrov
MBMarkus J. Bauer
Markus J. Bauer
MSMichael R. Stratton
Michael R. Stratton
The Tasmanian devil (Sarcophilus harrisii), the largest marsupial carnivore, is endangered due to a transmissible facial cancer spread by direct transfer of living cancer cells through biting. Here we describe the sequencing, assembly, and annotation of the Tasmanian devil genome and whole-genome sequences for two geographically distant subclones of the cancer. Genomic analysis suggests that the cancer first arose from a female Tasmanian devil and that the clone has subsequently genetically diverged during its spread across Tasmania. The devil cancer genome contains more than 17,000 somatic base substitution mutations and bears the imprint of a distinct mutational process. Genotyping of somatic mutations in 104 geographically and temporally distributed Tasmanian devil tumors reveals the pattern of evolution and spread of this parasitic clonal lineage, with evidence of a selective sweep in one geographical area and persistence of parallel lineages in other populations.

2 January 2023 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
NBNir Ben-Chetrit
Nir Ben-Chetrit
XNXiang Niu
Xiang Niu
ASAriel D. Swett
Ariel D. Swett
JSJesus Sotelo
Jesus Sotelo
MJMaria S. Jiao
Maria S. Jiao
DLDan A. Landau
Dan A. Landau

30 January 2018 in The Journal of Pathology
Verified
Journal Article
Open access
PDF file
CSCaitlin M Stewart
Caitlin M Stewart
PKPrachi D Kothari
Prachi D Kothari
FMFlorent Mouliere
Florent Mouliere
RMRichard Mair
Richard Mair
SSSaira Somnay
Saira Somnay
DTDana Wai Yi Tsui
Dana Wai Yi Tsui
Over the past decade, advances in molecular biology and genomics techniques have revolutionized the diagnosis and treatment of cancer. The technological advances in tissue profiling have also been applied to the study of cell‐free nucleic acids, an area of increasing interest for molecular pathology. Cell‐free nucleic acids are released from tumour cells into the surrounding body fluids and can be assayed non‐invasively. The repertoire of genomic alterations in circulating tumour DNA (ctDNA) is reflective of both primary tumours and distant metastatic sites, and ctDNA can be sampled multiple times, thereby overcoming the limitations of the analysis of single biopsies. Furthermore, ctDNA can be sampled regularly to monitor response to treatment, to define the evolution of the tumour genome, and to assess the acquisition of resistance and minimal residual disease. Recently, clinical ctDNA assays have been approved for guidance of therapy, which is an exciting first step in translating cell‐free nucleic acid research tests into clinical use for oncology. In this review, we discuss the advantages of cell‐free nucleic acids as analytes in different body fluids, including blood plasma, urine, and cerebrospinal fluid, and their clinical applications in solid tumours and haematological malignancies. We will also discuss practical considerations for clinical deployment, such as preanalytical factors and regulatory requirements. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

1 December 2018 in Cancer Genetics
Verified
Journal Article
Closed access
CSCaitlin M. Stewart
Caitlin M. Stewart
DTDana Wai Yi Tsui
Dana Wai Yi Tsui

23 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JWJonathan Wan
Jonathan Wan
DSDennis Stephens
Dennis Stephens
LLLingqi Luo
Lingqi Luo
JWJames R. White
James R. White
CSCaitlin M. Stewart
Caitlin M. Stewart
LDLuis A. Diaz
Luis A. Diaz
Mutational signatures accumulate in somatic cells as an admixture of endogenous and exogenous processes that occur during an individual’s lifetime. Since dividing cells release cell-free DNA (cfDNA) fragments into the circulation, we hypothesize that plasma cfDNA might reflect mutational signatures. Point mutations in plasma whole genome sequencing (WGS) are challenging to identify through conventional mutation calling due to low sequencing coverage and low mutant allele fractions. In this proof of concept study of plasma WGS at 0.3–1.5x coverage from 215 patients and 227 healthy individuals, we show that both pathological and physiological mutational signatures may be identified in plasma. By applying machine learning to mutation profiles, patients with stage I-IV cancer can be distinguished from healthy individuals with an Area Under the Curve of 0.96. Interrogating mutational processes in plasma may enable earlier cancer detection, and might enable the assessment of cancer risk and etiology.

7 July 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
PKPrachi Kothari
Prachi Kothari
FMFrancesco Marass
Francesco Marass
JYJulie L. Yang
Julie L. Yang
CSCaitlin M. Stewart
Caitlin M. Stewart
DSDennis Stephens
Dennis Stephens
DTDana Wai Yi Tsui
Dana Wai Yi Tsui
Purpose: The enucleation rate for retinoblastoma has dropped from over 95% to under 10% in the past 10 years as a result of improvements in therapy. This reduces access to tumor tissue for molecular profiling, especially in unilateral retinoblastoma, and hinders the confirmation of somatic RB1 mutations necessary for genetic counseling. Plasma cell‐free DNA (cfDNA) has provided a platform for noninvasive molecular profiling in cancer, but its applicability in low tumor burden retinoblastoma has not been shown. We analyzed cfDNA collected from 10 patients with available tumor tissue to determine whether sufficient tumorderived cfDNA is shed in plasma from retinoblastoma tumors to enable noninvasive RB1 mutation detection.Methods: Tumor tissue was collected from eye enucleations in 10 patients diagnosed with advanced intra‐ocular unilateral retinoblastoma, three of which went on to develop metastatic disease. Tumor RB1 mutation status was determined using an FDA‐cleared tumor sequencing assay, MSK‐IMPACT. Plasma samples were collected before eye enucleation and analyzed with a customized panel targeting all exons of RB1.Results: Tumor‐guided genotyping detected 10 of the 13 expected somatic RB1 mutations in plasma cfDNA in 8 of 10 patients (average variant allele frequency 3.78%). Without referring to RB1 status in the tumor, de novo mutation calling identified 7 of the 13 expected RB1 mutations (in 6 of 10 patients) with high confidence.Conclusion: Plasma cfDNA can detect somatic RB1 mutations in patients with unilateral retinoblastoma. Since intraocular biopsies are avoided in these patients because of concern about spreading tumor, cfDNA can potentially offer a noninvasive platform to guide clinical decisions about treatment, follow‐up schemes, and risk of metastasis.